A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.137, Iss.2, 2013-01, pp. : 471-482

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

By Iwata Hiroji Narabayashi Masaru Ito Yoshinori Saji Shigehira Fujiwara Yasuhiro Usami Shigeyuki Katsura Koichi Sasaki Yasutsuna

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 621-628

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study evaluating lapatinib in combination with nab -paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

By Yardley Denise

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 457-464

Springer Publishing Company

Access to resources Recommend Favorite

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

By Coombes R. C. Tat T. Miller M. L. Reise J. A. Mansi J. L. Hadjiminas D. J. Shousha S. Elsheikh S. E. Lam E. W-F. Horimoto Y. El-Bahrawy M. Aboagye E. O. Contractor K. B. Shaw J. A. Walker R. A. Marconell M. H. Palmieri C. Stebbing J.

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 924-930

Oxford University Press

Access to resources Recommend Favorite

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

By Lin Nancy Freedman Rachel Ramakrishna Naren Younger Jerry Storniolo Anna Bellon Jennifer Come Steven Gelman Rebecca Harris Gordon Henderson Mark MacDonald Shannon Mahadevan Anand Eisenberg Emily Ligibel Jennifer Mayer Erica Moy Beverly Eichler April Winer Eric

Breast Cancer Research and Treatment, Vol. 142, Iss. 2, 2013-11 ,pp. : 405-414

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2

By Giordano Sara B Kaklamani Virginia

Breast Cancer Management, Vol. 2, Iss. 6, 2013-11 ,pp. : 529-535

Future Medicine

Access to resources Recommend Favorite